Janus Henderson Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Janus Henderson Group’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-44,356	Closed	-$187K	–	2756
2023 Q1	$187K	Buy	44,356 +22,079	+99%	+$115K	﹤0.01%	2512
2022 Q4	$134K	Buy	+22,277	New	+$122K	﹤0.01%	2282

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Janus Henderson Group's CTIC Position: Q2 2023 in Review

Janus Henderson Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 44,356 shares — an estimated $187K sold.

Janus Henderson Group first reported a position in CTIC in Q4 2022 and held it in 2 quarters. The position peaked at $187K in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Janus Henderson Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Janus Henderson Group sold 44,356 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $187K.
Janus Henderson Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 2 quarters.
Janus Henderson Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $187K in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Janus Henderson Group's 13F filing for Q2 2023, filed 14 Aug 2023.